More evidence of cardiorenal protective effects of peroxisome proliferator-activated receptor activation

Hypertension

Volumn 46, Issue 2, 2005, Pages 267-268

  Schiffrin, Ernesto L ^a  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 20 HYDROXYICOSATETRAENOIC ACID; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; CLOFIBRATE; CYTOCHROME P450 4A; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; FIBRIC ACID DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; BLOOD PRESSURE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR SYSTEM; EDITORIAL; HEART PROTECTION; HYPERTENSION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RENAL PROTECTION;

ANIMALS; CARDIOTONIC AGENTS; HUMANS; KIDNEY DISEASES; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS;

EID: 23244468300     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000172756.41375.e4     Document Type: Editorial

References (21)

1. Bruissant O, Foufelle F, Scotto C, Dauca M, Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, -β, and -γ in the adult rat. Endocrinology. 1996; 137:354-366.
2. Bishop-Bailey D. Peroxisome proliferator-activated receptors in the cardiovascular system. Br J Pharmacol. 2000;129:823-834.
3. Schiffrin EL, Amiri F, Benkirane K, Iglarz M, Diep QN. Peroxisome proliferators-activated receptors: vascular and cardiac effects in hypertension. Hypertension. 2003;42:664-668.
4. Schiffrin EL. Peroxisome proliferator-activated receptors and cardiovascular remodeling. Am J Physiol. 2005;288:H1037-H1043.
5. Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf DJ, Umesono K, Evans RM. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci U S A. 1994;91:7355-7359.
6. Diep QN, Amiri F, Benkirane K, Paradis P, Schiffrin EL. Long-term effects of PPARγ activator pioglitazone on cardiac hypertrophy and inflammation in SHRSP. Can J Physiol Pharmacol. 2004;82:976-985.
7. Diep QN, El Mabrouk M, Cohn JS, Endemann D, Amiri F, Virdis A, Neves MF, Schiffrin EL. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-γ. Circulation. 2002;105:2296-2302.
8. Diep QN, Amiri F, Touyz RM, Cohn JS, Endemann D, Schiffrin EL. PPARα activator effects on Ang II-induced vascular oxidative stress and inflammation. Hypertension. 2002;40:866-871.
9. Diep QN, Benkirane K, Amiri F, Cohn JS, Endemann D, Schiffrin EL. PPARα activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats. J Mol Cell Cardiol. 2004;36:295-304.
10. Iglarz M, Touyz RM, Amiri F, Lavoie M-F, Diep QN, Schiffrin EL. Effect of peroxisome proliferator-activated receptor-α and -γ activators on vascular remodeling in endothelin-dependent hypertension. Arterioscl Thromb Vasc Biol. 2003;23:45-51.
11. Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, Gonzalez FJ, Fruchart JC, Tedgui A, Haegeman G, Staels B. Peroxisome proliferator-activated receptor α negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-κB and AP-1. J Biol Chem. 1999;274:32048-32054.
12. Ishibashi M, Egashira K, Hiasa Ki, Inoue S, Ni W, Zhao Q, Usui M, Kitamoto S, Ichiki T, Takeshita A. Antiinflammatory and antiarteriosclerotic effects of pioglitazone. Hypertension. 2002;40:687-693.
13. Marx N, Duez H, Fruchart JC, Staels B. Peroxisome Proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res. 2004;94:1168-1178.
14. Williams JM, Zhao X, Wang MH, Imig JD, Pollock DM. Peroxisome proliferator-activated receptor-alpha activation reduces salt-dependent hypertension during chronic endothelin B receptor blockade. Hypertension. 2005;46:366-371.
15. Gariepy CE, Ohuchi T, Williams SC, Richardson JA, Yanagisawa M. Salt-sensitive hypertension in endothelin-B receptor-deficient rats. J Clin Invest. 2000;105:925-933.
16. B receptor deficient rats. J Cardiovasc Pharmacol. 2004;44:S7-S10.
17. Kaasjager KA, Koomans HA, Rabelink TJ. Endothelin-1-induced vasopressor responses in essential hypertension. Hypertension. 1997;30:15-21.
18. Escalante BA, McGiff JC, Oyekan AO. Role of cytochrome P-450 arachidonate metabolites in endothelin signaling in rat proximal tubule. Am J Physiol. 2002;282:F144-F150.
19. Vera T, Taylor M, Bohman Q, Flasch A, Roman RJ, Stec DE. Fenofibrate prevents the development of angiotensin II-dependent hypertension in mice. Hypertension. 2005;45:730-735.
20. Alonso-Galicia M, Frohlich B, Roman RJ. Induction of P450A4 activity improves pressure-natriuresis in Dahl S rats. Hypertension. 1998;31:232-236.
21. Ma YH, Gebremedhin D, Schwartzman ME, Falck JR, Clark JE, Masters BS, Harder DR, Roman RJ. 20-Hydroxyeicosatetraenoic acid is an endogenous vasoconstrictor of canine renal arcuate arteries. Circ Res. 1993;72:126-136.